Investigational Immunotherapy Drug Shrinks Tumors in High-risk Neuroblastoma Patients
In a study of 34 children and teenage patients, neuroblastoma tumors shrank, some dramatically, after receiving an experimental monoclonal antibody produced on the St. Jude Children’s Research Hospital campus where the study is still underway. After completing therapy, 13 patients showed no evidence of disease. “The early response is very promising, among the best that we have seen against neuroblastoma, but we still have a long way to go,” said furst author Wayne Furman, MD, a member of the St. Jude Department of Oncology. “Will this translate into more clues? We hope so, but the answer is several years away.” To read more, click here.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
Computer Assisted Radiology and Surgery 31st International Congress and Exhibition
June 20-24, 2017; Barcelona, Spain
2017 New England Neurological Society Annual Meeting
June 22-24, 2017; Chatham, Mass.
June 29-30, 2017; Germany
2nd International Conference on Spine and Spinal Disorders
July 24-26, 2017; Rome, Italy